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Ora l  P resentat ions  
how weI1 peripheral counts predicted CD34 recovery during the 
first collection, linear regression was performed using WBC, 
platelet (Ph) count, and PCD34 count as independent variables. 
Data were log transformed. WBC and Plt both were correlated 
with CD34 yield (p of slope = 0.000 and 0.012, respectively). 
However, coefficients of correlation (r^2) were low (0.137 and 
O. 162) rendering these parameters of little value for predicting the 
behavior of the individual patient, in contrast, the correlation of 
CD34 yield and PCD34 count was stri~ng (rA2=0.958). Cross 
tabs analysis of PCD34 performed on the day of leukapheresis 
revealed that a cutoffof 10 PCD34/microliter gave a 92.6% prob- 
ability of collecting in a single leukapheresis, and a 98.8% proba- 
bility after 1 or more leukaphereses. We are using these data to 
construct an algorithm to schedule patients for leukapheresis, with 
particular attention to the difficult o mobilize patient. 
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ANTIGEN PRESENTING CELLS IN THE LIVER RECRUITE ACTIVATED 
ALLOGENEIC CDS+ T CELLS TO ELICIT HEPATIC GRAFT-VERSUS- 
HOST DISEASE 
ZhmTg, I( l; Shlomchik, D~D.:; Joe, G J; LoTtbo,ati11, JJ; Zhu, J. I; Gian- 
nola, D. ~ ; Enzerson, S.G. i 1. ~ledicine, University of PemT.~vlvania School 
of ~lediciJze, Philadelphia, PA; 2. ~}zle University, New Haven, CT. 
Graft-versus-host disease (GVHD) induced by donor T cells rec- 
og~aizing minor histcompatibility antigens (miHAs) primarily target 
specific organs uch as the liver, skin and intestine. YVe have previous- 
ly demonstrated that rapid activation donor T cells by host antigen 
presenting ceils (APCs) is ufficient o both activation and effector 
phases of acute GVHD. However, it is not well understood how 
these organs become the main targets of activated alloreactive T cells. 
In order to measure whether tissue resident APCs might play a criti- 
cal role in initiating the local development of acute GVHD, we selec- 
tively depleted host macrophages and DCs from the livers and 
spleens but not from the skin, peripheral lymph nodes (PLN), or 
mesenteric lymph nodes (MLN) of C57BL/6 (B6) mice by intra- 
venous administration f liposomal-ehlodronate prior to allogeneic 
bone marrow transplantation. Depletion of host hepatic and splenic 
macrophages and DCs significantly inhibited the proliferation of 
donor C3H.SW CDS+ T cells in the spleen but not in the PLN or 
MLN of B6 mice. Such organ-selective depletion of host tissue APCs 
also markedly reduced the trafficking of allogeneic CD8+ T cells into 
the livers and spleens, but not PLN and MLN, of B6 recipients as 
compared to hat of the control mice. Acute hepatic, but not cnta- 
neous, GVHD was inhibited as well, resulting in improved survival of 
liposomal-chlodronate tr ated B6 recipients. YVhen C3H.SW 
CD8+T cells were activated in normal B6 recipients, recovered and 
adoptively transferred into secondary B6 recipients, activated onor 
CD8+ T cells rapidly migrated into the livers and spleens of control 
B6 recipients, but was markedly decreased in B6 mice that were 
depleted of hepatic and splenic macrophages and DCs. Interestingly, 
host APC activation of donor T cells induced the expression of 
CCR5 followed by CCR1 and CCR4. In contrast, CCR7 that is 
expressed on naive T cells was dramatically reduced on these activat- 
ed CD8+ T cells. Thus, tissue resident APCs control the local 
recnlitment of allo-reactive donor T cells and the subsequent devel- 
opment of acute GVHD via the coordinated expression of chemokine 
receptor CCR7, CCR5 and CCR1 on actiwlted onor CD8 T cells. 
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A PHASE I/ll STUDY OF RECOMBINANT HUMAN KERATINOCYTE 
GROWTH FACTOR (KGF) IN PATIENTS WITH HIGH RISK HEMATO- 
LOGIC MALIGNANCIES UNDERGOING MISMATCHED RELATED OR 
UNRELATED DONOR TRANSPLANT 
Reynolds, C.M.; Fe~v:nr< ft.; Raymond, H.; B'~vntn, T.; Ratamnha'natholv, 
U.; Aysh, L.; Levine, ft.; }~anik, G.; Cooke, R~; Silvel; S.; Redo!y, P.; 
Beckel; ?,I.; Ube~Ti, ft. Ulfiversitv of Michiglm, Ann A'rbol, MI. 
In murine BMT systems, the administration of KGF reduces 
small bowel damage and serum systemic inflammatory mediators 
resulting in less clinical GVHD while preserving GVL and 
improving leukemia free survival. We initiated aphase I/II, sched- 
ule escalation trial of KGF plus standard GVHD prophylaxis 
(tacrolimus and methotrexate) in patients with an unrelated or 
tILA mismatched donor who are therefore at high risk for devel- 
oping acute GVHD (AGVHD). All study patients (n=I 1) had high 
risk hematologic malignancies. Patients received a full-intensity 
conditioning regimen of CVB (cyclophosphamide, VP-16, 
BCNU), BAC (busulfan, cytarabine, cyclophosphamide) or 
CyTBI (cyclophosphamide, TBI 1200 cGy). KGF (60 mcg/kg/day 
intravenously) was administered for 3 consecutive days prior to 
the conditioning regimen, and then for 3 consecutive days each 
week starting Day 0, escalating in 2 week blocks. One DLT has 
been observed (CTC grade 3 skin rash on Day +6), One patient 
with progressive NHL prior to transplant received only 3 doses 
and was removed from the study, and a second patient with pri- 
mary refractory NHL died of sepsis within two weeks of trans- 
plant. Nine patients are fidly evaluable for AGVHD (table). All 
four patients receiving 6 doses of KGF developed AGVHD (one 
each with overall grades 1 to 4). Of five patients receiving either 
12 or 18 doses of KGF, one patient had grade 1 and one had grade 
2 AGVHD. Six patients are in remission at last follow-up. These 
preliminary results at the higher KGF doses compare fnvorably to 
historical controls in which the incidence of AGVHD is 50 to 
75% in patients receiving unrelated or HLA-mismatched allo- 
grafts. The study continues to accrue patients and will escalate the 
administration schedule of KGF up to 36 doses based on the inci- 
dence of DLTs. 
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SIROLIMUS (RAPAMYCIN) FOR TREATMENT OF STEROID-REFRACTO- 
RY CHRONIC GRAFT VERSUS HOST DISEASE 
Com'iel, D.R.; Hicks, 1C; Saliba, R.; Cohen, A.; It)politi, C.; Hsu, 1:; 
Donato, ~i.; Gi~vlt, S.; Khom'i, L; Hosing', C.; De LiTna, :~l.ff.; Ander- 
sson, B.; Gajewski, ft.; Ne~mzmm, ft.; CTJampliJl, R. Blood and 3/lmv'ozv 
Transplantation, UT ~ID Anderson Cancer Center, Hozzsron, TX. 
Chronic graft versus host disease (cGVHD) occnrs in approxi- 
mately 50% of patients following hematopoietic stem cell trans- 
plant. VVe conducted a phase II trial in 29 patients with steroid- 
refractory cGVHD (median age 42 years, range 18-69) utilizing 
tacrolimusin combination with sirolimns. At the time of sirolimus 
initiation, 20 patients (69%) had extensive cGVHD, and 9 
patients hinited. Disease sites included: lower GI tract (n=2), liver 
(n=6), skin (n=24), oral/vaginal mucosae (n=5), ocular (n=3), and 
upper GI tract (n=l). Eight patients had s~n involvement (30%) 
with scleroderma. The onset of eGVHD at study enrolhnent 
included 15 relapsing" (52%), 12 progressive (42%), and 2 (7%) de 
novo cases. All patients had failed multiple previous lines of 
immunosuppression (median 4, range 2-14) prior to sirolimus. 
Patients received sirolirnus uspension orally at a loading dose of 6 
rag, followed by a maintenance dose of 2 nag/day to maintain 
trough concentrations of 5-15 mg/dl. Additional monitoring 
inchided weekly lipid panels, }LMG CoA reductase inhibitors and 
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